Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

A Randomized, Double-Blind, Parallel-Group, Virtual Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics for the Prevention of Episodic Migraine in Late Adolescents and Adults Currently Receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

Study Overview

• Status: Active, not recruiting
• Conditions: Migraine; Headache; Headache, Migraine; Episodic Migraine
• Intervention / Treatment: Device: Click Digital Therapeutic

Detailed Description

The purpose of this randomized trial is to evaluate the efficacy and safety of two prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adolescents and adults who are receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Research Coordinator; Phone Number: 877-352-5425; Email: researchcoordinator@clicktherapeutics.com

Study Locations

• United States
  • New York
    • New York, New York, United States, 10013
      • Click Therapeutics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• A participant will be eligible for entry into the study if all of the following criteria are met per participant self-report:
• Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.
• Lives in the United States.
• Adult or late adolescent, ≥ 18 years of age at the time of informed consent.
• Able to read and understand the English informed consent form.

• The following will be investigator-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD), 3rd Edition:

  i. Age of onset of migraines prior to 50 years of age

ii. Migraine attacks, on average, lasting 4-72 hours if untreated

iii. Per participant report, 4 or more migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days)

iv. Four to fourteen migraine days during the run-in period

• Is currently managing migraines with at least 1 prescription CGRP inhibitor therapy for the preventive or acute treatment of episodic or chronic migraine during the 3 months prior to screening.
• Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later, and is willing to download and use the specified eDiary and Study App required by the protocol.
• Is willing and able to receive SMS text messages and push messages on their smartphone.
• Is the owner of, and has regular access to, an email address.
• Has regular access to the Internet via cellular data plan and/or wifi.
• Understands the use of and interest in the eDiary and the Study App during the screening period and the baseline visit (Day 1).

Exclusion Criteria:

• A participant will not be eligible for study entry if any of the following criteria are met per participant self-report:
• History of basilar migraine or hemiplegic migraine.
• Active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS).
• Other pain syndromes (including trigeminal neuralgia), psychiatric conditions (such as current major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.
• History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months (48 weeks) or having met DSM-5 criteria for any significant substance use disorder within the past 12 months (48 weeks) from the date of the screening visit.
• History of use of analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen, including opioids) or butalbital on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit or during the run-in period.
• Post-traumatic headache, persistent post-traumatic headache, or post-concussion syndrome.
• Other significant acute or chronic medical condition(s) that, in the opinion of the Investigator, may confound the interpretation of findings to inform PDT development.
• Failure to adhere with or inability to complete eDiary inputs and onboarding activities during the run-in period. Participants who are not adherent during the run-in period are not eligible for study entry.
• Previous enrollment in any digital therapeutics pilot or pivotal study for a migraine indication.
• Participation in any other investigational clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ReMMiD-C Therapeutic Arm A; Mobile application A (ReMMiD-C Digital Therapeutic) as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.	Device: Click Digital Therapeutic; Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
Experimental: ReMMiD-C Therapeutic Arm B; Mobile application B as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.	Device: Click Digital Therapeutic; Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Monthly Migraine Days (MMDs)	Change from baseline in the number of Monthly Migraine Days (MMDs) at Week 12	Baseline to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Patients with Decrease in MMDs	Proportion of participants who have at least a 50% reduction from baseline in the mean number of MMDs at Week 12	Baseline to Week 12
Change in MMDs at Weeks 4 and 8	Change from baseline in the number of MMDs recorded over the previous 28 days at Week 4 and Week 8	Baseline to Weeks 4 and 8
Change in Mean MMDs	Reduction from baseline in the mean number of MMDs over 12 weeks	Baseline to Week 12
Change in Average Headache Severity	Change in the average severity of headache from the run-in period to Weeks 9-12	Run-in to Weeks 9-12
Change in Migraine Questionnaire	Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v2.1 (MSQ) at Week 4, Week 8, and Week 12	Baseline to Weeks 4, 8 and 12
Change in Migraine Disability Assessment (MIDAS)	Change from baseline in the Migraine Disability Assessment (MIDAS) at Week 4, Week 8, and Week 12	Baseline to Weeks 4, 8, and 12
Change in Migraine Medication Use (frequency)	Change in the use (frequency) of acute migraine medications from the run-in period to Weeks 9-12	Run-in to Weeks 9-12
Change in Migraine Medication Use (dose)	Change in the use (dose) of acute migraine medications from the run-in period to Weeks 9-12	Run-in to Weeks 9-12
Change in Migraine Medication Use (medication type)	Change in the use (type) of acute migraine medications from the run-in period to Weeks 9-12	Run-in to Weeks 9-12

Collaborators and Investigators

• Sponsor: Click Therapeutics, Inc.
• Investigators: Study Director: Shaheen Lakhan, Click Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): July 21, 2023
• Primary Completion (Estimated): May 21, 2024
• Study Completion (Estimated): June 12, 2024

Study Registration Dates

• First Submitted: July 26, 2023
• First Submitted That Met QC Criteria: August 15, 2023
• First Posted (Actual): August 22, 2023

Study Record Updates

• Last Update Posted (Actual): March 8, 2024
• Last Update Submitted That Met QC Criteria: March 6, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: CGRP; Smartphone app; Software as a Medical Device (SaMD); Prescription digital therapeutic (PDT); Calcitonin Gene-Related Peptide Inhibitor Therapy
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Headache Disorders, Primary; Headache Disorders; Migraine Disorders; Headache
• Other Study ID Numbers: CT-132-R-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No